Literature DB >> 33149355

Comparison of the efficacy of 2 sedative protocols in pediatric dogs undergoing brainstem auditory-evoked response testing.

Alejandra García de Carellán Mateo1, Elena Ríos Álvarez1, Carlos Ros1.   

Abstract

This study compared the quality of sedation with dexmedetomidine or alfaxalone during brainstem auditory-evoked response (BAER) tests in 6- to 17-week-old dogs. This was a prospective, randomized clinical study involving 19 client-owned pediatric dogs of breeds with reported congenital deafness. Group A (GA) received alfaxalone, 2 mg/kg body weight (BW) (n = 9) and group D (GD) dexmedetomidine, 0.005 mg/kg BW, and postprocedure antagonism with atipamezole (n = 10) intramuscularly. Time from injection to sedation, duration of sedation, sedation scores, need for re-dosing, rectal temperature, pulse and respiratory rate were recorded at baseline, before and after the BAER test, and once recovered from sedation. Pulse rate was significantly lower in GD (P = 0.004) and the number of re-dosing was significantly higher in GA (P = 0.011). Both sedation protocols allowed good quality BAER test recordings in pediatric dogs. Sedation with dexmedetomidine required less re-dosing, whereas alfaxalone maintained more physiological pulse rates. Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33149355      PMCID: PMC7560758     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  21 in total

1.  Comparison of the brainstem auditory evoked responses during sevoflurane or alfaxalone anaesthesia in adult cats.

Authors:  Carlos Ros; Carme Soler; Alejandra García de Carellán Mateo
Journal:  Vet Anaesth Analg       Date:  2017-03-02       Impact factor: 1.648

2.  Reference values of the brainstem auditory evoked response of methoxyflurane anesthetized and unanesthetized dogs.

Authors:  L J Myers; R W Redding; S Wilson
Journal:  Vet Res Commun       Date:  1985-09       Impact factor: 2.459

3.  Evaluation of the occurrence of canine congenital sensorineural deafness in puppies of predisposed dog breeds using the brainstem auditory evoked response.

Authors:  Marta Płonek; Elżbieta Giza; Artur Niedźwiedź; Krzysztof Kubiak; Józef Nicpoń; Marcin Wrzosek
Journal:  Acta Vet Hung       Date:  2016-12       Impact factor: 0.955

4.  Auditory brainstem of the ferret: maturation of the brainstem auditory evoked response.

Authors:  A L Morey; S Carlile
Journal:  Brain Res Dev Brain Res       Date:  1990-03-01

5.  Clinical evaluation of alfaxalone as an anaesthetic induction agent in dogs less than 12 weeks of age.

Authors:  Bj O'Hagan; K Pasloske; C McKinnon; Nr Perkins; T Whittem
Journal:  Aust Vet J       Date:  2012-07-24       Impact factor: 1.281

6.  Onset and quality of sedation after intramuscular administration of dexmedetomidine and hydromorphone in various muscle groups in dogs.

Authors:  Jennifer E Carter; Crace Lewis; Thierry Beths
Journal:  J Am Vet Med Assoc       Date:  2013-12-01       Impact factor: 1.936

7.  Impact of Injection Speed, Volume, and Site on Pain Sensation.

Authors:  Eric Zijlstra; Johannes Jahnke; Annelie Fischer; Christoph Kapitza; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2017-10-08

8.  The pharmacological effects of the anesthetic alfaxalone after intramuscular administration to dogs.

Authors:  Jun Tamura; Tomohito Ishizuka; Sho Fukui; Norihiko Oyama; Kodai Kawase; Kenjiro Miyoshi; Tadashi Sano; Kirby Pasloske; Kazuto Yamashita
Journal:  J Vet Med Sci       Date:  2014-11-27       Impact factor: 1.267

9.  Sedation levels in dogs: a validation study.

Authors:  Marika C Wagner; Kent G Hecker; Daniel S J Pang
Journal:  BMC Vet Res       Date:  2017-04-18       Impact factor: 2.741

10.  A comparison of the brainstem auditory evoked response in healthy ears of unilaterally deaf dogs and bilaterally hearing dogs.

Authors:  M Plonek; J Nicpoń; K Kubiak; M Wrzosek
Journal:  Vet Res Commun       Date:  2016-11-29       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.